
If you have $10,000 ready to invest, putting it into high-quality ASX growth shares can be a smart way to build long-term wealth.
However, you can’t just put it in any old share. The key is focusing on businesses with scalable models, strong tailwinds, and the ability to keep growing earnings over time.
While there will always be volatility along the way, the right companies can reward patient investors.
Here are three ASX growth shares that analysts think could be worth considering.
Pro Medicus Ltd (ASX: PME)
The first ASX growth share that could be a standout pick is Pro Medicus.
It operates in medical imaging software and has built a reputation as one of the highest-quality growth companies on the ASX.
What makes it particularly compelling is its business model. The company wins large, long-term contracts with hospitals and healthcare providers, creating recurring revenue and strong visibility over future earnings.
It also operates with very high margins, which means a large portion of its revenue flows through to profit.
The team at Bell Potter thinks recent share price weakness has created a buying opportunity. Earlier this week, it put a buy rating and $226.00 price target on its shares.
Life360 Inc (ASX: 360)
Another ASX growth share that could be worth considering is Life360.
Life360 has built a global platform focused on family safety and location sharing, with almost 100 million active users.
The company is increasingly monetising its platform through subscriptions, partnerships, advertising, and new services. This is underpinning significant recurring revenue.
And with management confident that 2026 will see further strong user growth, Life360 looks likely to deliver another year of stellar revenue and profit growth.
Bell Potter is also bullish on this one and recently put a buy rating and $35.50 price target on its shares.
WiseTech Global Ltd (ASX: WTC)
A third ASX growth share that could be worth considering is WiseTech Global.
It provides software solutions for the global logistics industry, with its CargoWise platform deeply embedded in customer operations.
This creates strong switching costs and recurring revenue, both of which are attractive traits in a growth company.
The company continues to expand its product offering and global reach, positioning itself at the centre of increasingly complex supply chains.
With global trade becoming more digitised, WiseTech has a long runway for growth.
Last week, the team at Morgan Stanley put an overweight rating and $70.00 price target on its shares.
The post 3 ASX growth shares to buy with $10,000 appeared first on The Motley Fool Australia.
Should you invest $1,000 in Life360 right now?
Before you buy Life360 shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Life360 wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why AMP, Life360, Netwealth, and Ora Banda shares are racing higher today
- Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?
- 5 ASX ETFs that could supercharge your portfolio
- One ASX share to double, one yielding 11% â ASX picks for April
- 2 ASX 200 shares down 30%+ that I’d buy with $4,000
Motley Fool contributor James Mickleboro has positions in Life360, Pro Medicus, and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Life360 and WiseTech Global. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.